Supplementary Figure 2:
Summary of transcriptional analyses of inflammatory factors in mast cell lines before and after estradiol treatment. Human mast cell lines HMC-1 and LAD2 were treated with 100 nM estradiol (E 2 ) for 24 hours. RNA samples from control (untreated) and E 2 -treated cells were reverse transcribed and analyzed using RT2 Profiler PCR array "Human cytokines and chemokines" (Qiagen, covers 84 inflammatory genes). Expression data of detectable genes are presented as a fold regulation in comparison to controls. Upregulation and downregulation ("-") values more than 2-fold are highlighted in red and blue, respectively. HMC-1 cells, which possess through CpG-promoter methylation inactivated estrogen receptors, ESR1 and ESR2, responded to E 2 -excess with more than 2-fold downregulation of 21 out of 32 detectable inflammatory factors (7 genes exhibited unchanged transcription levels and 2 genes were upregulated). In contrast, LAD2 cells possessing unmethylated and active ESR1 and ESR2, responded to E 2 with upregulation of 15 out of 32 detectable inflammatory factors (14 genes exhibited unchanged transcription levels and 3 genes were downregulated). Abbreviations: ILs: interleukins; CCLs: C-C motif chemokines; CXCLs: C-X-C motif chemokines; BMPs: bone morphogenetic proteins; CSF3: colony stimulating factor 3; IFNs: interferons; MSTN: myostatin; SPP1: secreted phosphoprotein 1; TNFRSF11B: tumor necrosis factor receptor superfamily member 11B; TNFSF11: tumor necrosis factor superfamily member 11; VEGFA: vascular endothelial growth factor alpha.
Supplementary Figure 3:
Summary of CpG-promoter methylation analyses of inflammatory factors in mast cell lines before and after estradiol treatment. DNA from untreated (control) and estradiol treated (100 nM, 24 hours) mast cell lines HMC-1 and LAD2 was bisulfite-converted and analyzed using EpiTect Methyl II Signature PCR array "Human cytokine production" (Qiagen, covers 22 inflammatory genes) and by pyrosequencing (6 genes) with ready-to-use primer sets (Qiagen) for indicated genes (note: AR and CXCR4 were analyzed in two different promoter regions). High levels of promoter methylation were found in control LAD2 cells in 10 genes and in control HMC-1 cells in 11 (indicated in green). For most inflammatory genes, E 2 treatment did not have an effect on DNA methylation. However, four out of 28 analyzed genes showed significant changes (50% and 37% decrease of methylation in LAD2 cells in GATA3 and INHA, respectively; 61% and 56% increase of methylation in HMC cells in BCL3 and TLR2, respectively). Abbreviations (gene with noticeable methylation and methylation changes are listed): BCL3: B-cell CLL/Lymphoma 3; ELANE: elastase, neutrophil expressed; FOXP3: forkhead box P3; GATA3: GATA binding protein 3; IGF2BP2: Insulin-like growth factor 2 mRNA-binding protein 2; INHA: inhibin A; INHBA: inhibin beta A subunit; LTB: lymphotoxin beta; SMAD3: SMAD family member 3; STAT5A: Signal transducer and activator of transcription 5A; TLR2: toll-like receptor 2; CXCL12: C-X-C motif chemokine 12; ER1: estrogen receptor alpha; ER2: estrogen receptor beta; AR: androgen receptor; IL13: interleukin 13; N/A: not applicable as did not pass the quality control.
